Introduction
============

The germ-line breast cancer 1 interacting protein 1 (*BRIP1*) comes to light as a crucial protein for BRCA1-dependent DNA damage repair functions \[[@r1]-[@r3]\]. The human *BRIP1* gene (also named *FANCJ* or *BACH1*) is located on chromosome 17q22, comprising of 19 introns and 20 exons, and encodes BRCA1-associated C-terminal helicase 1 \[[@r1],[@r4]\] And its mutations that affect helicase activity have been identified in patients suffering early-stage breast cancer. Missense mutations in *BRIP1* may increase breast cancer risk \[[@r5]\]. Therefore, it is considered as a moderate-penetrance susceptibility gene for breast cancer. However, previous studies declared that *BRIP1* mutation not only has effect on breast cancer, but also in other various cancers including cervical cancer \[[@r5]-[@r7]\], ovarian cancer \[[@r4],[@r8]\] and prostate cancer \[[@r9]\].

It is observed that the genetic polymorphisms in BRIP1 influence the cancer susceptibility by altering their natural function. And many single-nucleotide polymorphisms (SNPs) in *BRIP1* have been recognized. SNPs may alter the expression, processing, and transcription of genes, and thus contribute to cancer development. Numerous epidemiological studies have demonstrated that some SNPs located within genes can alter their expression and/or maturation and are associated with cancer susceptibility and progression.

Recently, numerous molecular epidemiology studies explored the relationship between *BRIP1* polymorphisms and cancer susceptibility. Nevertheless, their results were inconclusive. Polymorphisms of *BRIP1* is regarded as an important susceptibility factor in cervical cancer, but not in breast cancer \[[@r5]-[@r7]\]. For example, Due to the inconsistencies among these previous studies, we conducted this meta-analysis covering all eligible molecular epidemiology studies to validate the correlation of four most common *BRIP1* polymorphisms (rs2048718, rs4988344, rs4986764, and rs6504074) and cancer risk.

RESULTS
=======

Study characteristics
---------------------

According to our inclusion criteria, 18 studies from 15 articles containing 13,716 cancer patients and 15,590 cancer-free controls were finally included. The detail screening process was exhibited in [Figure 1](#f1){ref-type="fig"}. It contained four separate studies in Song's articles focusing on breast cancer and ovarian cancer.

![**The flow diagram of the meta-analysis.** CNKI: China National Knowledge Infrastructure.](aging-10-101388-g001){#f1}

Among the 18 eligible studies, 11 were conducted in Caucasian populations from the UK, Italy, Germany, USA, Canada, Denmark, Cyprus, and Finland. Five studies were on Asian background and all samples were Chinese. And one study was performed on mixed population. All the studies were case-control design, studying on various cancer types including breast, ovarian, cervical, gastric and prostate cancer. [Table 1](#t1){ref-type="table"} listed the main characteristics of all included studies.

###### Characteristics of the studies included in the meta-analysis.

  ------------------------------- ------ --------- ----------- ------------- -------------------- ------------ -------------- ---------
  Study                           Year   Country   Ethnicity   Cancer type   Genotyping medthod   Source of\   Case/Control   SNP No.
                                                                                                  control                     

  Carrera-Lasfuentes \[[@r20]\]   2017   Spain     Mixed       GC            QIAamp               Population   598/601        3

  Zhou \[[@r21]\]                 2014   China     Asian       CC            MassARRAY            Population   309/315        1, 3

  Ren \[[@r14]\]                  2013   China     Asian       BC            Mass ARRAY           Hospital     319/306        1,2,3,4

  Ma 1 \[[@r6]\]                  2013   China     Asian       CC            Mass ARRAY           Population   454/562        1,2,3,4

  Ma 2 \[[@r5]\]                  2013   China     Asian       CC            Mass ARRAY           Hospital     298/286        1,2,3,4

  Silvestri \[[@r22]\]            2011   Italy     Caucasian   BC            PCR-SSCP             Hospital     97/203         3

  Loizidou \[[@r23]\]             2010   Cyprus    Caucasian   BC            MassArray            Population   1108/1170      3

  Huo \[[@r24]\]                  2009   China     Asian       BC            PCR-PIRA             Population   568/624        3

  Kote-Jarai \[[@r9]\]            2009   UK        Caucasian   PC            TaqMan               Population   1841/1880      4

  Guénard \[[@r25]\]              2008   Canada    Caucasian   BC            PCR-RFLP             Hospital     96/70          1,3

  Song 1 \[[@r4]\]                2007   UK        Caucasian   BC            TaqMan               Population   2270/2280      1,2

  Song 2 \[[@r4]\]                2007   UK        Caucasian   OC            TaqMan               Population   730/855        1,2,4

  Song 3 \[[@r4]\]                2007   USA       Caucasian   OC            TaqMan               Population   327/429        1,2,4

  Song 4 \[[@r4]\]                2007   Denmark   Caucasian   OC            TaqMan               Population   456/1231       1,2,4

  Frank \[[@r26]\]                2007   Germany   Caucasian   BC            TaqMan               Population   571/712        1,3

  Garcia-Closas \[[@r20]\]        2006   Mixed     Caucasian   BC            qPCR                 Population   1596/1254      3

  Vahteristo \[[@r27]\]           2006   Finland   Caucasian   BC            TaqMan               Population   866/731        3

  Seal \[[@r28]\]                 2006   UK        Caucasian   BC            Pyrosequencing       Population   1212/2081      3
  ------------------------------- ------ --------- ----------- ------------- -------------------- ------------ -------------- ---------

**Abbreviations** BC: breast cancer; CC: cervical cancer; PC: Prostate cancer; OC: ovarian cancer; PCR: polymerase chain reaction; RFLP: restriction fragment length polymorphism. PIRA: PCR-primer introduced restriction analysis; DHPLC, denaturing high -performance liquid chromatography; SSCP: single strand conformation polymorphism; SNP: single-nucleotide polymorphisms; SNP No.1: rs2048718; 2: rs4988344; 3: rs4986764; 4.rs6504074

Quantitative synthesis of the four polymorphisms
------------------------------------------------

As [Table 2](#t2){ref-type="table"} showed, the frequencies of the minor allele (MAF) in the cancer-free controls varied widely across included studies, ranging from 0.23 to 0.62 for rs2048718, 0.14 to 0.62 for rs4988344, 0.26 to 0.60 for rs4986764, and 0.24 to 0.28 for rs6504074. The average frequencies of the minor allele for the four abovementioned polymorphisms were 0.39, 0.35, 0.40, and 0.26, respectively.

###### BRIP1 polymorphisms Genotype Distribution and Allele Frequency in this meta-analysis.

  ------------------------- -------------- ---------------------- --------- ------- ------ ------ ------ ----- ------ ------ ------ ------ ------ ------
  Study                     Genotype (N)   Allele frequency (N)   MAF                                                                             
  Case                      Control        Case                   Control   HWE                                                                   
  total                     AA             AB                     BB        total   AA     AB     BB     A     B      A      B                    
  **rs2048718**                                                                                                                                   
  Zhou 2014                 309            196                    94        19      314    183    118    13    486    132    484    144    0.23   0.26
  Ren 2013                  319            201                    98        20      305    177    115    13    500    138    469    141    0.23   0.29
  Ma 1 2013                 454            285                    141       28      560    326    208    26    711    197    860    260    0.25   0.32
  Ma 2 2013                 298            188                    92        18      285    166    106    13    468    128    438    132    0.23   0.45
  Guénard 2008              96             38                     41        17      70     23     32     15    117    75     78     62     0.41   0.54
  Song 1 2007               2170           655                    1063      452     2264   655    1151   458   2373   1967   2461   2067   0.47   0.24
  Song 2 2007               722            236                    341       145     847    246    425    176   813    631    917    777    0.50   0.76
  Song 3 2007               322            91                     157       74      421    131    195    95    339    305    457    385    0.51   0.17
  Song 4 2007               429            118                    215       96      1209   352    632    225   451    407    1336   1082   0.62   0.05
  Frank 2007                571            181                    283       107     712    228    340    144   645    497    796    628    0.49   0.40
  **rs4988344**                                                                                                                                   
  Ren 2013                  319            65                     145       109     306    43     148    115   275    363    234    378    0.62   0.67
  Ma 1 2013                 454            92                     207       155     562    84     270    208   391    517    438    686    0.61   0.81
  Ma 2 2013                 297            60                     136       101     286    42     138    106   256    338    222    350    0.61   0.79
  Song 1 2007               2189           1552                   585       52      2278   1609   616    53    3689   689    3834   722    0.16   0.51
  Song 2 2007               729            498                    203       28      848    589    239    20    1199   259    1417   279    0.16   0.46
  Song 3 2007               323            228                    86        9       427    309    103    15    542    104    721    133    0.16   0.09
  Song 4 2007               278            188                    82        8       712    526    174    12    458    98     1226   198    0.14   0.58
  **rs4986764**                                                                                                                                   
  Carrera-Lasfuentes 2017   598            232                    297       69      601    224    270    107   761    435    718    484    0.40   0.11
  Zhou 2014                 309            164                    116       29      315    136    146    33    444    174    418    212    0.34   0.50
  Ren 2013                  319            168                    120       31      306    132    141    33    456    182    405    207    0.34   0.61
  Ma 1 2013                 454            247                    165       42      562    240    258    64    659    249    738    386    0.34   0.67
  Ma 2 2013                 298            160                    110       28      286    122    132    32    430    166    376    196    0.34   0.68
  Silvestri 2011            97             37                     49        11      203    82     95     26    123    71     259    147    0.36   0.85
  Loizidou 2010             1108           465                    502       141     1170   475    534    161   1432   784    1484   856    0.37   0.58
  Huo 2009                  568            308                    227       33      624    345    232    47    843    293    922    326    0.26   0.36
  Guénard 2008              96             18                     48        30      70     12     32     26    84     108    56     84     0.60   0.69
  Frank 2007                571            181                    295       95      712    226    365    121   657    485    817    607    0.43   0.20
  Garcia-Closas 2006        1596           529                    761       306     1254   406    612    236   1819   1373   1424   1084   0.43   0.84
  Vahteristo 2006           866            184                    428       254     731    148    382    201   796    936    678    784    0.54   0.17
  Seal 2006                 1212           462                    549       201     2081   783    970    328   1473   951    2536   1626   0.39   0.34
  **rs6504074**                                                                                                                                   
  Ren 2013                  319            203                    95        21      304    176    110    18    501    137    462    146    0.24   0.88
  Ma 1 2013                 454            288                    137       29      558    317    205    36    713    195    839    277    0.25   0.71
  Ma 2 2013                 298            188                    92        18      284    162    104    18    468    128    428    140    0.25   0.81
  Kote-Jarai 2009           1841           963                    727       151     1880   1031   727    122   2653   1029   2789   971    0.26   0.68
  Song 2 2007               725            417                    270       38      847    457    325    65    1104   346    1239   455    0.27   0.50
  Song 3 2007               324            170                    117       37      421    225    156    40    457    191    606    236    0.28   0.09
  Song 4 2007               260            137                    104       19      650    340    258    52    378    142    938    362    0.28   0.76
  ------------------------- -------------- ---------------------- --------- ------- ------ ------ ------ ----- ------ ------ ------ ------ ------ ------

**Abbreviations** A: the major allele, B: the minor allele. MAF: minor allele frequencies.

[Table 3](#t3){ref-type="table"} listed the results of this meta-analysis. There were 10 studies with 5,690 cancer patients and 6,087 healthy individuals for rs2048718. As displayed in [Table 3](#t3){ref-type="table"} and [Figure 2](#f2){ref-type="fig"}, rs2048718 polymorphism had a decrease risk of overall cancer based on the heterozygous and dominant models (AB vs. AA: OR = 0.90, 95% CI = 0.83--0.97, *P* = 0.008; AB+BB vs. AA: OR = 0.92, 95%CI = 0.86--0.99, *P* = 0.037). In the stratified analysis by ethnicity, the results showed significant associations between rs2048718 and cancer risk in the Asian population by heterozygous and dominant comparison (AB vs. AA: OR = 0.76, 95% CI = 0.65--0.89, *P* = 0.001; AB+BB vs. AA: OR = 0.82, 95%CI = 0.70--0.95, *P* = 0.008), while no association was found among Caucasians. However, in the stratified analysis by cancer types, we found a decrease risk between rs2048718 and cervical cancer under heterozygous and dominant model (AB vs. AA: OR = 0.76, 95% CI = 0.64--0.91, *P* = 0.003; AB+BB vs. AA: OR = 0.82, 95%CI = 0.69--0.97, *P* = 0.021), and the results showed no significant difference between rs2048718 polymorphism and gynecologic (breast and ovarian) cancer susceptibility.

###### Meta-analysis results.

  --------------- ------------------ ------------- ------------------ ------------- ------------------- ------------- ------------------- ------------ ------------------- -------------
  Comparisons     B vs A             BB vs AA      AB vs AA           BB vs AA+AB   AB+BB vs AA                                                                            
  OR (95%CI)      *P*                OR (95%CI)    *P*                OR (95%CI)    *P*                 OR (95%CI)    *P*                 OR (95%CI)   *P*                 
  rs2048718       0.98(0.93--1.03)   0.408         1.02(0.92--1.14)   0.704         0.90(0.83--0.97)    **0.008**     1.05 (0.96--1.16)   0.269        0.92(0.86--0.99)    **0.037**
  Caucasian       0.99(0.89--1.12)   0.921         0.99(0.89--1.12)   0.921         0.95(0.86--1.04)    0.274         1.03 (0.93--1.14)   0.595        0.96(0.88--1.05)    0.381
    Asian         0.91(0.81--1.04)   0.160         1.28(0.92--1.80)   0.147         0.76(0.65--0.89)    **0.001**     1.42 (1.02--1.97)   0.040        0.82(0.70--0.95)    **0.008**
    CC            0.91(0.79--1.05)   0.209         1.26(0.86-1.85)    0.228         0.76(0.64-0.91)     **0.003**     1.39(0.96--2.03)    0.084        0.82(0.69-0.97)     **0.021**
    BC            0.98(0.91--1.05)   0.479         0.98(0.85--1.13)   0.771         0.92(0.82-1.03)     0.151         1.02 (0.90--1.15)   0.820        0.94(0.84--1.04)    0.21
    OC            1.01(0.92-1.11)    0.772         1.04(0.86--1.26)   0.665         0.96(0.82-1.11)     0.563         1.07(0.91-1.26)     0.410        0.98(0.85-1.13)     0.775
  rs4988344       0.97(0.87--1.09)   0.620         0.89(0.67--1.18)   0.418         0.94(0.80--1.10)    0.441         0.95(0.82-1.10)     0.468        0.93(0.79--1.11)    0.430
  Caucasian       1.03(0.93-1.14)    0.533         1.18(0.89--1.57)   0.260         1.03(0.93--1.14)    0.533         1.17(0.88--1.55)    0.282        1.44 (0.99--2.08)   0.38
    Asian         0.68(0.54-0.86)    **0.001**     0.66(0.52--0.85)   **0.001**     0.68 (0.54--0.86)   **0.001**     0.88 (0.74--1.04)   0.132        0.78 (0.62--0.97)   **\<0.001**
    BC            0.92(0.77-1.11)    0.395         0.81(0.51-1.30)    0.391         0.85(0.57-1.25)     0.405         0.93(0.72-1.19)     0.542        0.87(0.56-1.34)     0.519
    OC            1.14(0.99-1.30)    0.063         1.41(0.92-2.14)    0.114         1.11(0.94-1.30)     0.211         1.37(0.90-2.09)     0.139        1.63(0.98-2.72)     0.059
  **rs4986764**   0.94(0.90-0.98)    **0.001**     0.90(0.82--0.99)   0.024         0.89 (0.80--0.99)   **0.025**     0.95 (0.87--1.03    0.203        0.88(0.80--0.97)    **0.009**
  Caucasian       0.99(0.94--1.04)   0.700         0.98(0.88--1.10)   0.779         0.96 (0.89--1.05)   0.361         1.01 (0.92--1.12)   0.781        0.97 (0.90--1.05)   0.426
  Chinese         0.81(0.73--0.89)   **0.004**     0.71 (0.56-0.88)   **0.002**     0.73 (0.57--0.93)   **0.011**     0.82(0.66--1.02)    0.072        0.72(0,59-0.90)     **0.004**
  CC              0.74(0.65-0.84)    **\<0.001**   0.67(0.50-0.89)    **0.006**     0.64 (0.53-076)     **\<0.001**   0.83(0.63-1.09)     0.175        0.64 (0.54--0.77)   **\<0.001**
  BC              0.98(0.93--1.03)   0.406         0.96(0.87--1.07)   0.481         0.96 (0.89--1.03)   0.253         1.00 (0.91--1.09)   0.958        0.96(0.89--1.03)    0.244
  **rs6504074**   0.96(0.85--1.09)   0.556         1.04(0.89--1.23)   0.614         0.94 (0.87--1.03)   0.197         1.06 (0.91--1.25)   0.457        0.92(0.79--1.08)    0.298
  Caucasian       1.09 (1.00-1.21)   0.059         1.01(0.70--1.44)   0.978         1.02 (0.92--1.12)   0.766         1.01 (0.73--1.40)   0.953        1.08(0.97--1.20)    0.171
  Chinese         0.84(0.73--0.97)   **0.016**     0.91(0.64--1.30)   0.610         0.75(0.62--0.89)    **0.002**     1.01(0.71-1.43)     0.939        0.77(0.65--0.91)    **0.003**
  OC              1.02(0.87--1.20)   0.787         0.86(0.65--1.13)   0.269         0.95 (0.82--1.11)   0.513         0.87(0.67--1.14)    0.325        1.01 (0.83--1.24)   0.911
  GC              0.90(0.82-0.98)    0.015         0.88(0.71-1.09)    0.236         0.86(0.77-0.97)     0.011         0.92(0.75-1.14)     0.463        0.86(0.77-0.96)     0.008
  --------------- ------------------ ------------- ------------------ ------------- ------------------- ------------- ------------------- ------------ ------------------- -------------

**Abbreviations** A: the major allele; B: the minor allele; CI: confidence interval; OR: odds ratio; GC: gynecologic cancer; BC: breast cancer;OC: ovarian cancer.

![**Forest plot of OR with 95%CI for the BRIP1 polymorphisms with cancer risk under dominant model rs2048718.** CI: confidence interval, OR: odds ratio.](aging-10-101388-g002){#f2}

There were 7 studies containing 4,589 cancer cases and 5,419 cancer-free controls for rs4988344. As shown in [Table 3](#t3){ref-type="table"}, The pooled analysis displayed no association of any genetic models and overall cancer risk (All *P* \> 0.05). In subgroup analysis by ethnicity, we detected a significant association among Chinese people in four genetic models (B vs. A: OR = 0.68, 95% CI = 0.54--0.86, *P* = 0.001; BB vs. AA: OR = 0.66, 95% CI = 0.54--0.86, *P* = 0.001; AB vs. AA: OR = 0.88, 95% CI = 0.54--0.86, *P* = 0.001; AB+BB vs. AA: OR = 0.78, 95% CI = 0.63--0.97, *P* \< 0.001).

Thirteen studies covering 8,092 cases and 8,915 controls were pooled to evaluate the correlation of rs4986764 and cancer risk. Showing in [Table 3](#t3){ref-type="table"} and [Figure 3](#f3){ref-type="fig"}, rs4986764 was associated to reduce cancer risk among the overall population by allele comparison (OR = 0.94, 95% CI = 0.90--0.98, *P* = 0.001), heterozygous comparison (OR = 0.89, 95% CI = 0.80--0.99, *P* = 0.025), and dominant comparison (OR = 0.88, 95% CI = 0.80--0.97, *P* = 0.009). Stratified analysis by ethnicity also displayed significant differences in Chinese population (B vs. A: OR = 0.81, 95% CI = 0.73--0.89, *P* = 0.004; BB vs. AA: OR = 0.71, 95% CI = 0.56--0.88, *P* = 0.005; AB vs. AA: OR = 0.77, 95% CI = 0.57--0.93, *P* = 0.011; AB+BB vs. AA: OR = 0.72, 95% CI = 0.59--0.90, *P* = 0.004). However, there was no significant correlation found in Caucasians for all genetic models (all *P* \> 0.05). In the stratified analysis by cancer types, all genetic models failed to detect significant correlations in breast cancer. However, a statistical significance suggested that rs4986764 polymorphism may decrease cervical cancer risk (B vs. A: OR = 0.74, 95% CI = 0.65--0.84, *P* \< 0.001; BB vs. AA: OR = 0.67, 95% CI = 0.50--0.89, *P* = 0.006; AB vs. AA: OR = 0.64, 95% CI = 0.53--0.76, *P* \< 0.001; AB+BB vs. AA: OR = 0.64, 95% CI = 0.54--0.77, *P* = 0.0001).

![**Stratified analysis based on ethnicity for the association between BRIP1 rs4986764 polymorphism and cancer risk using dominant model.** (**A**) based on ethnicity; (**B**) based on cancer type. CI: confidence interval, OR: odds ratio.](aging-10-101388-g003){#f3}

A total of 7 studies for rs6504074 included 4,221 cases and 4,944 controls. As shown in [Table 3](#t3){ref-type="table"}, the overall analysis showed no association between rs6504074 between cancer risk in any genetic models (All *P*﹥0.05). But, further stratification analysis by ethnicity indicated that rs6504074 was significantly associated with a lower cancer risk among Chinese population by three models (B vs. A: OR = 0.84, 95% CI = 0.73--0.97, *P* = 0.016; AB vs. AA: OR = 0.75, 95% CI = 0.62--0.89, *P* = 0.002; BB + AB vs. AA: OR = 0.77, 95% CI = 0.65--0.91, *P* = 0.003). The subgroup analysis by cancer type of rs6504074 also showed a reduced risk for gynecologic cancers in allele model (OR = 0.90, 95% CI = 0.82--0.98, *P* = 0.015), heterozygous model (OR = 0.88, 95% CI = 0.77--0.97, *P* = 0.011), and dominant model (OR = 0.86, 95% CI = 0.77--0.96, *P* = 0.008).

Heterogeneity analysis and publication bias
-------------------------------------------

The results of the heterogeneity test are displayed in [Table 4](#t4){ref-type="table"}. When the *P* value of the heterogeneity tests was less than 0.1 (*P* \< 0.1), a random effects model was selected. Otherwise a fixed-effect model was applied.

###### Heterogeneity-analysis results.

  ------------- -------- ---------- ---------- ------------- ------------- ------ ------- ------- ------ ------- ------- ------ ------- ------- ---
  Comparisons   B vs A   BB vs AA   AB vs AA   BB vs AA+AB   AB+BB vs AA                                                                        
  I^2^          *P*      EM         I^2^       *P*           EM            I^2^   *P*     EM      I^2^   *P*     EM      I^2^   *P*     EM      
  rs2048718     0.0%     0.729      F          0.0%          0.679         F      4.6%    0.399   F      0.0%    0.629   F      0.0%    0.557   F
  Caucasian     0.0%     0.448      F          0.0%          0.470         F      0.0%    0.998   F      0.0%    0.59    F      0.0%    0.493   F
  Chinese       0.0%     1.000      F          0.0%          0.990         F      0.0%    0.572   F      0.0%    0.991   F      0.0%    0.999   F
  CC            0.0%     0.998      F          0.0%          0.972         F      0%      0.982   F      0.0%    0.963   F      0.0%    0.993   F
  BC            0.0%     0.805      F          0.0%          0.682         F      0%      0.443   F      0.0%    0.525   F      0.0%    0.641   F
  OC            45.0%    0.162      F          42.0%         0.179         F      27%     0.253   F      11.5%   0.323   F      42.1%   0.178   F
  rs4988344     55.5%    0.036      R          52.9%         0.047         R      55.0%   0.038   R      5.6%    0.384   F      63.3%   0.430   R
  Caucasian     27.7%    0.246      F          15.8%         0.312         F      6.7%    0.359   F      11.7%   0.334   F      89.9%   0.000   R
  Chinese       0.0%     0.975      F          0.0%          0.963         F      0.0%    0.964   F      0.0%    0.994   F      0.0%    0.428   F
    BC          55.6%    0.134      R          59.0%         0.118         R      67.5%   0.080   R      0.0%    0.512   F      74.8%   0.046   R
    OC          0.0%     0.404      F          12.6%         0.319         F      0.0%    0.374   F      14.0%   0.312   F      89.0%   0.000   R
  rs4986764     45.9%    0.036      F          6.8%          0.378         F      52.8%   0.013   R      12.2%   0.323   F      50.6%   0.019   R
  Caucasian     0.0%     0.980      F          0.0%          0.980         F      0.0%    0.991   F      0.0%    0.887   F      0.0%    0.998   F
  Chinese       37.5%    0.171      F          0.0%          0.974         F      70.5%   0.009   R      0.0%    0.989   F      66.1%   0.019   R
    BC          0.0%     0.787      F          0.0%          0.939         F      0.0%    0.589   F      0.0%    0.857   F      0.0%    0.691   F
    CC          0.0%     0.912      F          0.0%          0.932         F      0.0%    0.964   F      0.0%    0.949   F      0.0%    0.939   F
  rs6504074     52.4%    0.062      R          39.2%         0.130         F      41.2%   0.116   F      26.2%   0.229   F      55.4%   0.047   R
  Caucasian     0.0%     0.967      F          66.7%         0.029         R      0.0%    0.645   F      62.0%   0.048   R      0.0%    0.740   F
  Chinese       0.0%     0.567      F          0.0%          0.936         F      0.0%    0.987   F      0.0%    0.935   F      0.0%    0.984   F
  OC            0.0%     0.551      F          48.8%         0.142         F      0.0%    0.840   F      45.6%   0.159   F      0.0%    0.794   F
    GC          0.0%     0.527      F          0.0%          0.534         F      0.0%    0.486   F      0.0%    0.516   F      0.0%    0.535   F
  ------------- -------- ---------- ---------- ------------- ------------- ------ ------- ------- ------ ------- ------- ------ ------- ------- ---

In this meta-analysis, we used funnel plots and Egger's test to estimate publication bias. The funnel plots ([Figure 4](#f4){ref-type="fig"}) failed to discover any prominent asymmetry for the four polymorphisms, which was consistent with the results of Egger's test (*P* \> 0.05). Therefore, we considered that the publication bias in this meta-analysis was not significant.

![**Funnel plots of publication bias.** (**A**) rs2048718; (**B**) rs4988344; (**C**) rs4986764; (**D**) rs6504074.](aging-10-101388-g004){#f4}

Sensitivity analysis
--------------------

The sensitivity analysis was used in rs4986764 showed no individual research could alter the pooled ORs significantly ([Figure 5](#f5){ref-type="fig"}), which proved the reliability and credibility of the outcomes.

![Sensitivity analysis of the associations between rs4986764 polymorphisms and cancer risk.](aging-10-101388-g005){#f5}

DISCUSSION
==========

As a DNA helicase interacts with *BRCA1* directly, *BRIP1* regulates DNA normal double-strand break repair function \[[@r1],[@r4]\]. Germline *BRIP1* mutations, which negatively affect DNA repair and genomic stability, and thus increase the likelihood of cancer development, have been reported to be connected with breast, colon, prostate and ovarian cancer \[[@r4],[@r8],[@r12],[@r13]\]. Recent studies showed that SNPs in genes had an influence on multiple types of cancer \[[@r4]-[@r6],[@r14]\]. Numerous previous studies have suggested that *BRIP1* polymorphisms were potentially related to susceptibility of human cancers, especially breast, cervical, and ovarian cancer. However, these published studies reported inconsistent results \[[@r7]\], probably due to the limitations, such as small sample size, mixed ethnic groups, and cancer types. To our knowledge, there are few researches have simultaneously estimated the relationship between common variants in *BRIP1* and the risks of common cancers. With a sample size of 13,716, our meta-analysis showed the overall associations between common polymorphisms of *BRIP1* (rs2048718, rs4988344, rs4986764, and rs6504074) and cancer risk. The pooled analysis found significant association with rs2048718 and rs4986764. And, we found all these 4 SNPs predicted a decreased risk of cancer in Chinese. Moreover, rs6504074 showed an association with gynecologic cancer. And, rs2048718 and rs4986764 polymorphisms showed a decreased risk of cervical cancer.

Compared to other published meta-analyses, we found both consistent and conflicting results. Based on the results of 2 studies in USA and Poland using mouthwash samples, rs4986764 (P919S) had no association with breast cancer \[[@r15]\]. In another meta-analysis, Shi et al reported that rs4986764 may reduce the breast cancer risk for the Caucasian population, especially postmenopausal females who has a family history of breast cancer excluding mutations of BRCA1/2 \[[@r16]\]. However, no association was found in Pabalan's study \[[@r17]\]. Unfortunately, their meta-analysis failed to analyze the data according to ethnic subgroup. Previous studies failed to find a relation between rs2048718 and rs4988344 polymorphisms and the susceptibility of cervical cancer \[[@r5],[@r6],[@r14]\]. Our study showed that rs4988344 polymorphism has no significant influence on cancer risk among overall population, while subgroup analysis by ethnicity showed a significant association in the Chinese population ([Table 3](#t3){ref-type="table"}). The most important polymorphisms of *BRIP1* (rs2048718, rs4988344, rs4986764, and rs6504074) were associated with cancer risk among Chinese; however, no significant relationship was observed in Caucasians. We presumed that this discrepancy may have resulted from variations in the genomes of different ethnic groups. These results suggest that ethnic differences and the patient's environment may play a role in malignancy. On account of the findings of these studies, we estimated the possible association between the 4 SNPs of *BRIP1* and cancer risk. However, *in vivo*, *BRIP1* might be regulated by multiple mechanisms \[[@r1],[@r18],[@r19]\]. We speculated that discrepancy for *BRIP1* in different ethnic groups stems from a diversity regulating mechanism as well.

As to the limitations of this meta-analysis, absence of detailed information and adjusted outcomes should be acknowledged. We failed to considered detailed information like age, sex, lifestyle, and environmental exposures. Besides, we found a decreased risk of rs2048718 and rs4986764 polymorphisms to cervical cancer based on three studies, which needs further well-design multicenter studies including more study subjects to confirm.

CONCLUSIONS
===========

Overall, this meta-analysis showed that rs2048718 and rs4986764 were associated with a lower cancer risk among overall population. According to the stratified analysis by ethnicity, the rs2048718, rs4988344, rs4986764 and rs6504074 polymorphisms of *BRIP1* were strongly related to cancer susceptibility among Chinese population. And rs6504074 was significant associated with gynecologic cancer. These may made SNPs of *BRIP1* (rs2048718, rs4988344, rs4986764, and rs6504074) be a potential tool for cancer screening and improve early cancer diagnosis.

MATERIALS AND METHODS
=====================

Search strategy
---------------

A profound literature search from PubMed, Web of Science, WanFang, VIP and Chinese National Knowledge Infrastructure (CNKI) databases was conducted up until December 31, 2017, applying the search terms: cancer/tumor/carcinoma/neoplasm, BRIP1, and polymorphism/genotype /SNP. The reference of literature review and eligible articles were also screened for additional relevant publication. Studies conformed to the following criteria were selected: (1) case-control design estimating the relationship of *BRIPI* SNPs and cancer risk; (2) full-text study; (3) all cancer cases confirmed by histopathology, and all cancer-free controls without history of malignant diseases; (4) published in English or Chinese; (5) detailed genotyping data offered. Review papers, not case-control design or studies lack of detailed gene data were excluded. If overlapping cases or controls appeared in two or more different studies, the paper with larger sample size was finally chosen.

Data extraction
---------------

Two reviewers (Liu Di and Wang Meng) reviewed included articles independently. The following information was collected from each included publication: first author, publication year, country or origin, ethnicity, source of control, total number of cases and controls, genotyping methods, genetic distribution of cases and controls group, and P value of Hardy--Weinberg equilibrium (HWE) for controls. Ethnic groups were categorized as Caucasian, Asian, African, and "mixed." All case and control groups were well controlled. Data with discrepancies were discussed with a senior author until consensus reached.

Statistical analysis
--------------------

To measure the associations between *BRIP1* polymorphisms and cancer risk, odds ratio (OR) with 95% conﬁdence interval (CI) was calculated according to the genotypes in cases and controls. The signiﬁcance of the pooled OR was determined by the Z test. All *P* values in this study were two-sided, and a statistic significance was considered if *P* \< 0.05. All statistical analyses in our investigation were performed by the software STATA (Version 12.0, Stata Corp, College Station, TX).

The meta-analysis assessed the associations using 5 different genetic models \[[@r10],[@r11]\]: homozygous model (BB vs. AA), heterozygous model (AB vs. AA), dominant model (BB+ AB vs. AA), recessive model (BB vs. AA+ AB), and allele model (B vs. A). "A", "B" represents the major, minor allele, respectively. Statistical heterogeneity among included studies was evaluated by the Q and I^2^ statistics. Publication bias was accessed with funnel plots and Egger's test. Sensitivity analysis was conducted to access the statistic stability of polymorphisms including more than 10 studies, by sequentially excluding every individual research and re-checked whether the pooled ORs were changed.
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